• 1.

    Epelboin Y, Talaga S, Epelboin L, Dusfour I, 2017. Zika virus: an updated review of competent or naturally infected mosquitoes. PLoS Negl Trop Dis 11: e0005933.

    • Search Google Scholar
    • Export Citation
  • 2.

    Wikan N, Smith DR, 2016. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 16: e119e126.

  • 3.

    Moore CA 2017. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr 171: 288295.

  • 4.

    Adebanjo T 2017. Update: interim guidance for the diagnosis, evaluation, and management of infants with possible congenital Zika virus infection—United States, October 2017. MMWR Morb Mortal Wkly Rep 66: 10891099.

    • Search Google Scholar
    • Export Citation
  • 5.

    Safronetz D Contributors, 2017. Evaluation of 5 commercially available Zika virus immunoassays. Emerg Infect Dis 23: 15771580.

  • 6.

    Lindsey NP 2017. Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and U.S. territories in 2016. J Clin Microbiol 56: pii: e01115–17.

    • Search Google Scholar
    • Export Citation
  • 7.

    de Vasconcelos ZFM, Azevedo RC, Thompson N, Gomes L, Guida L, Moreira MEL, 2018. Challenges for molecular and serological ZIKV infection confirmation. Childs Nerv Syst 34: 7984.

    • Search Google Scholar
    • Export Citation
  • 8.

    Lee WT 2017. Development of Zika virus serological testing strategies in New York State. J Clin Microbiol 56: pii: e01591–17.

  • 9.

    Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, Lazear HM, de Silva AM, 2017. Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection. Emerg Infect Dis 23: 773781.

    • Search Google Scholar
    • Export Citation
  • 10.

    Buekens P ZIPH Working Group, 2016. Zika virus infection in pregnant women in Honduras: study protocol. Reprod Health 13: 82.

  • 11.

    San Martín JS, Brathwaite O, Zambrano B, Solórzano JO, Bouckenooghe A, Dayan GH, Guzmán MG, 2010. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 82: 128135.

    • Search Google Scholar
    • Export Citation
  • 12.

    Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR, 2008. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 14: 12321239.

    • Search Google Scholar
    • Export Citation
  • 13.

    Johnson BW, Russell BJ, Lanciotti RS, 2005. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 43: 49774983.

    • Search Google Scholar
    • Export Citation
  • 14.

    Pridjian G 2016. Prospective study of pregnancy and newborn outcomes in mothers with West Nile illness during pregnancy. Birth Defects Res A Clin Mol Teratol 106: 716723.

    • Search Google Scholar
    • Export Citation
  • 15.

    Lieberman MM 2009. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 16: 13321337.

    • Search Google Scholar
    • Export Citation
  • 16.

    WHO, 2016. Zika virus infection: global update on epidemiology and potentially associated clinical manifestations. Wkly Epidemiol Rec 91: 7381.

    • Search Google Scholar
    • Export Citation
  • 17.

    Rabe IB 2016. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep 65: 543546.

 

 

 

 

Zika Virus and the World Health Organization Criteria for Determining Recent Infection Using Plaque Reduction Neutralization Testing

View More View Less
  • 1 Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana;
  • 2 Departamento de Laboratorio Clínico, Hospital Escuela Universitario, Tegucigalpa, Honduras;
  • 3 Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal (IAV), Tegucigalpa, Honduras;
  • 4 Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina;
  • 5 Región Sanitaria Metropolitana del Distrito Central, Secretaría de Salud de Honduras, Tegucigalpa, Honduras;
  • 6 Instituto de Investigaciones en Microbiología, Centro de Investigaciones Genéticas (CIG), Escuela de Microbiología, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras

The recent Zika virus (ZIKV) epidemic swept across Latin America and the Caribbean, where dengue virus (DENV) is endemic. The antigenic similarities of these closely related flaviviruses left researchers and clinicians with challenges to interpret serological tests. Thirty-six women attending a prenatal clinic in Honduras and with positive DENV IgM enzyme-linked immunoabsorbent assays (ELISAs) were screened with a ZIKV immunoglobulin M ELISA, reverse transcription polymerase chain reaction for ZIKV and DENV 1–4, and plaque reduction neutralization tests (PRNTs) for ZIKV and DENV-2. Plaque reduction neutralization test results were interpreted using the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Using the WHO criteria of a PRNT90 titer ≥ 20 and a 4-fold difference between ZIKV and DENV titers, we determined that 69.4% of samples had a recent ZIKV infection, compared with 5.6% using CDC criteria. The interpretation of ZIKV PRNTs in a DENV-endemic region is highly dependent on the choice of interpretation criteria.

Author Notes

Address correspondence to Matthew J. Ward, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, Suite 2300, 1440 Canal St. #8317, New Orleans, LA 70112. E-mail: mward11@tulane.edu

Authors’ addresses: Matthew J. Ward, Pierre Buekens, and Dawn M. Wesson, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, E-mails: mward11@tulane.edu, pbuekens@tulane.edu, and wesson@tulane.edu. Jackeline Alger and Jorge García, Departamento de Laboratorio Clínico, Hospital Escuela Universitario, Tegucigalpa, Honduras, and Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal (IAV), Tegucigalpa, Honduras, E-mails: jackelinealger@gmail.com and jalgar62_84@yahoo.com.ar. Mabel Berrueta, Maria Luisa Cafferata, and Alvaro Ciganda, Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, E-mails: mberrueta@iecs.org.ar, marialuisa.cafferata@gmail.com, and aciganda@gmail.com. Harry Bock, Región Sanitaria Metropolitana del Distrito Central, Secretaría de Salud de Honduras, Tegucigalpa, Honduras, E-mail: hbockme@hotmail.com. Kimberly García, Ivette Lorenzana, and Leda Parham, Instituto de Investigaciones en Microbiología, Centro de Investigaciones Genéticas (CIG), Escuela de Microbiología, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras, E-mails: kimfa_2010@hotmail.com, ivettelorenzana@yahoo.com, and lparham29@hotmail.com. Wendy Lopez, Departamento de Laboratorio Clínico, Hospital Escuela Universitario, Tegucigalpa, Honduras, E-mail: wlopez36@hotmail.com.

Save